EVP-ABD: AN IMPROVED LIVER SPECIFIC AGENT FOR MRI

EVP-ABD：一种改进的 MRI 肝脏特异性药物

• 批准号: 6209545
• 负责人: Phillip Harnish
• 金额: $ 10.59万
• 依托单位: EAGLE VISION PHARMACEUTICAL CORPORATION
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-09-15 至 2001-09-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6209545
• 关键词: bioimaging /biomedical imaging; contrast media; liver cells; liver disorder diagnosis; magnetic resonance imaging; manganese; pharmacokinetics; technology /technique development

Liver disease remains a major challenge for accurate differential diagnosis. Several different types of lesions are commonly found in the liver. The liver is a prime focus for metastatic extension of numerous malignancies. Often, both benign and malignant lesions co-exist. It is critical for optimal treatment planning and follow-up to clearly differentiate each lesion type. Despite advances in technology, a large number of lesions are missed or incorrectly diagnosed. There remains a clear need for improved imaging agents that maximize the capabilities of the rapidly evolving diagnostic technologies. Eagle Vision Pharmaceutical Corp. (EVPC) is developing an agent that addresses unmet needs for the improved differential diagnosis for diseases of the liver and abdomen. EVP-ABD is a manganese (Mn) based magnetic resonance imaging (MRI) contrast agent designed to be taken up by hepatocytes and eliminated in the bile. The unique magnetic and kinetic properties of EVP-ABD are anticipated to provide high levels of enhancement for both the blood vessels and liver cells. This should overcome current limitations to the use of MRI for liver imaging and provide better information to discriminate between various malignant and benign lesions. This Phase I program will define the fundamental utility of EVP-ABD for liver imaging, confirming its feasibility as an improved agent. PROPOSED COMMERCIAL APPLICATIONS: The long-term goal of this research is to register EVP-ABD in the U.S. and elsewhere as a contrast agent for liver and abdominal MRI. By combining the vascular enhancement and kinetics of ECF agents with the tissue and lesion specific patterns of enhancement of hepatocellular agents, EVP- ABD should provide a more cost-effective, less invasive and more accurate diagnosis than current alternatives.

肝脏疾病仍然是准确鉴别诊断的主要挑战。几种不同类型的病变常见于肝脏。肝脏是许多恶性肿瘤转移扩展的主要病灶。通常，良性病变和恶性病变并存。明确区分每种病变类型对于最佳治疗计划和后续治疗至关重要。尽管技术进步，但仍有大量病变被遗漏或误诊。显然，仍然需要改进的成像试剂，以最大限度地发挥快速发展的诊断技术的能力。Eagle Vision制药公司(EVPC)正在开发一种试剂，以满足改善肝脏和腹部疾病鉴别诊断的未得到满足的需求。EVP-ABD是一种基于锰的磁共振成像(MRI)造影剂，旨在被肝细胞摄取，并在胆汁中消除。EVP-ABD独特的磁性和动力学特性有望为血管和肝细胞提供高水平的增强。这将克服目前使用MRI进行肝脏成像的局限性，并为区分各种恶性和良性病变提供更好的信息。该第一阶段计划将确定EVP-ABD在肝脏成像中的基本用途，确认其作为改进试剂的可行性。建议的商业应用：这项研究的长期目标是在美国和其他地方注册EVP-ABD作为肝脏和腹部MRI的造影剂。通过将ECF试剂的血管增强和动力学与肝细胞药物的组织和病变特异性增强模式相结合，EVP-ABD应该比目前的替代方案提供更具成本效益、更少侵入性和更准确的诊断。